Riesgo de acidosis láctica fatal y no fatal con el uso de metformina para la diabetes mellitus tipo 2
Characteristics of included studies Interventions
TREATMENT: Metformin, dosage unclear, + insulin COMPARISON: placebo + insulin
Outcomes
Daily dose insulin, and HbA1.
Notes Allocation concealment
B
Study
Wulffele 2002
Methods
TRIAL DESIGN: Double-blind randomised controlled trial DURATION: 48 months
Participants
COUNTRY: The Netherlands SETTING: outpatient Treatment N: 171 Control N: 182 Age: 60 +/- 10 Sex: 45% m4n Inclusion: type 2 DM controlled with insulin Exlcusions: renal insufficiency with GFR < 50, congestive heart failure
Interventions
TREATMENT: metformin, dose adjusted clinically, + insulin COMPARISON: placebo + insulin
Outcomes
Insulin requirements, lipid profile, glycemic control
Notes Allocation concealment
D
Study
Wulffele 2003
Methods
TRIAL DESIGN: Double-blind randomised controlled trial DURATION: 4 months
Participants
COUNTRY: The Netherlands SETTING: outpatient Treatment N: 196 Control N; 194 Inclusion: type 2 DM Exlcusions: renal insufficiency with GFR < 50, congestive heart failure, pregnancy
Interventions
TREATMENT: metformin, dose adjusted clinically COMPARISON: placebo
Outcomes
Homocystein, folate, vitamin B12, body weight, glycemic control
Notes Allocation concealment
D
Study
Wulffele 2005
Methods
TRIAL DESIGN: Double-blind randomised controlled trial DURATION: 4 months
Página 94
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.